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Objective: The study intended to substantiate healthcare resource utilization, costs, and
funding patterns of US and Canadian Friedreich’s Ataxia (FRDA) populations, to assess com-
pliance with treatment guidance and to identify areas where novel healthcare measures or
improved access to existing care may improve patients’ functional and social capabilities
and reduce the financial impact on the healthcare systems.
Methods: Healthcare resource utilization and costs were collected in a cross-sectional
study in the US (N =197) and Canada (N =43) and analyzed across severity of disease cat-
egories. Descriptive statistics, correlation analysis, and hypothesis testing were applied.
Results: In the US, healthcare costs of FRDA patients were higher than those of “adults
with two and more chronic conditions.” Significantly higher costs were incurred in advanced
stages of the disease, with paid homecare being the main driver. This pattern was also
observed in Canada. Compliance with the recommended annual neurological and cardio-
logical follow-up was high, but was low for the recommended regular speech therapy. In
the US public and private funding ratios were similar for the FRDA and the general popu-
lations. In Canada the private funding ratio for FRDA was higher than average.
Conclusion:The variety of healthcare measures addressing the broad range of symptoms
of FRDA, and the increasing use of paid home care as disease progresses made total US
healthcare costs of FRDA exceed the costs of US adults with two and more chronic con-
ditions. Therefore, measures delaying disease progression will allow patients to maintain
their independence longer and may reduce costs to the healthcare system. Novel mea-
sures to address dysarthria and to ensure access to them should be further investigated.
The higher than average private funding ratio in Canada was due to the relatively high cost
of the pharmacological treatment of FRDA.
Keywords: Friedreich ataxia, resource utilization, healthcare resource, rare diseases, cross-sectional studies, cost
of illness
BACKGROUND
RARE DISEASE
Friedreich’s Ataxia (FRDA) is one of the 6000–8000 rare diseases
currently known. It occurs in Caucasians with an average preva-
lence of 3–4 in 100,000 cases (Schulz et al., 2009), a figure well
below the threshold set by orphan drug regulations in Europe and
the United States to classify a disease as rare.
CLINICAL PICTURE
Friedreich’s Ataxia is a rare, inherited, progressive neurodegener-
ative multi-system disease that is characterized by a debilitating
loss of balance and coordination in all four limbs, which leads
to dependence on a wheelchair usually within 10–15 years after
disease onset. Cardiac involvement is seen in most patients, with
cardiomyopathy occurring mostly in patients with early disease
onset for whom it may be life threatening. Skeletal abnormal-
ities such as scoliosis and pes cavus are common. About 10%
of the patients develop diabetes mellitus. Dysarthria (slow, jerky
speech with sudden utterances) is seen in almost all patients, usu-
ally beginning shortly after disease onset and progressing until
speech becomes almost unintelligible. Vision loss is experienced
frequently, as is hearing impairment. Hearing loss is mainly seen
in later stages of the disease. Disease onset usually takes place in
the first two decades of life, but later onsets are seen, too. The
further progress is unremitting, but frequently includes periods of
stability at the beginning of the illness. Life expectancy of persons
with FRDA is reduced to 40–50 years (Pandolfo, 2009; Schulz et al.,
2009).
DIAGNOSIS AND TREATMENT
Diagnosis is made based on clinical symptom presentation and
with confirmation of FRDA by genetic testing. Treatment is largely
symptomatic. Supportive care is provided by a wide variety of
healthcare practitioners to help with Activities of Daily Living and
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to increase the health related quality of life of the affected persons.
In addition, patients in Canada have had access to the orphan
drug Catena® (INN: idebenone), the first pharmacotherapy for
FRDA, since its approval in 2008. (This approval was withdrawn
from the Canadian market by the end of April 2013 due to the
failure of additional clinical studies to confirm the efficacy claim.)
At the time of the study, Catena® was not approved in the United
States. Neurologists, cardiologists, general practitioners, ophthal-
mologists, and other specialists are consulted for diagnosis and
ongoing management of the neurological and non-neurological
symptoms of FRDA. Physiotherapy, speech therapy, and other
non-physician services address functional impairments. The range
of medical devices used includes wheelchairs and walking aids,
braces for the feet and spine, and hearing aids. Surgery may be
required to address skeletal deformities, and cardiac conditions
may lead to hospitalizations. Adaptations to the car and home
are made to facilitate the patients’ moving about. Pharmacological
agents are taken to manage conditions of the nervous, muscu-
loskeletal, cardiovascular, and the genitourinary systems and of
the metabolism, to name the most important areas. And finally,
as the disease progresses and family and friends may no longer be
able to cope with the challenges of the care, paid homecare and
stays in long-term care facilities may become necessary (Schulz
et al., 2009).
OBJECTIVES
The present study intended to enhance the healthcare commu-
nity’s understanding of FRDA patients’healthcare resource utiliza-
tion and related cost impact on the concerned healthcare systems.
The rate of monitoring visits to neurologists and cardiologists,
as well as the extent of utilization of physio and speech therapy
addressing ataxia and dysarthria, most characteristic and highly
disabling symptoms of FRDA, were assessed for compliance with
treatment guidance established by a panel of European experts
(Schulz et al., 2009). The data were also evaluated with the goal to
identify areas where novel healthcare measures or improved access
to existing care may enhance patients’ functional and social capa-
bilities and reduce the financial impact on the healthcare systems.
The private and public funding ratios were compared for persons
with FRDA and the general population to identify any discrep-
ancies. This study came second to a study on healthcare resource
utilization of FRDA patients in the United Kingdom and Germany
(Giunti et al., 2013).
METHODS
STUDY DESIGN AND MEASURED CONCEPTS
Retrospective, cross-sectional surveys were conducted in the
United States and Canada in persons with FRDA. The observation
period covered 12 months, most of which was in 2010. The study
adopted the perspective of the healthcare systems. Therefore, mea-
sured concepts were limited to direct medical and non-medical
costs which were paid by public and private insurance, as well as
out of pocket by the patients and their families. They included
a total of 11 healthcare components: physician and therapist ser-
vices, laboratory analyses,prescription medicines,devices,hospital
admissions including the use of emergency rooms, car and home
adaptations, paid homecare, and stays in long-term care facilities.
SURVEY SAMPLES
Estimates based on published prevalence ratios suggest the popula-
tion of FRDA to amount to between 5000 and 10,000 persons in the
United States and between 300 and 750 persons in Canada. To mit-
igate anticipated difficulties to achieve adequate sample sizes when
using a limited number of insurance claims databases the survey
participants were recruited from patient registries: in the United
States, the patient registry of FARA, the Friedreich Ataxia Research
Alliance, a large not for profit organization dedicated to furthering
research in FRDA, was used. The Canadian survey recruited the
participants among the registrants of a patient support program
offered to patients who sought treatment with Catena®. Inclu-
sion criteria in both surveys consisted of a genetic confirmation
of FRDA and residence in the respective country. Adult caregivers
were allowed to fill the questionnaire on behalf of minor patients.
QUESTIONNAIRE
To enhance the content validity of the questionnaire it was built
to reflect treatment recommendations set up by a panel of experts
from a European perspective (Schulz et al., 2009). The lack of
treatment guidelines specifically taking a US and/or Canadian per-
spective was compensated for by having the survey questionnaire
reviewed and approved by the Executive Director of the Friedre-
ich Ataxia Research Foundation FARA, located in the US, and
by an expert genetic counselor in Canada. Twenty one closed
questions addressed the diagnostic, medical treatment, and care
options which would most widely be used by persons with FRDA.
To further construct validity the respondents were offered pre-
defined frequency options to inform about the level of use they
made of the different services during the observation period. The
questionnaires were tested by patients and medical experts.
STUDY PROCEDURES
The patients were asked to fill either an electronic or a paper ques-
tionnaire to inform about selected demographics, their current
status of disease severity (measured as degree of wheelchair use), as
well as their quantitative utilization of resources across 11 health-
care components. With the exception of the costs of car and home
adaptations, patients were not asked to report costs. For the US
survey these were sourced from the Centers of Medicare & Med-
icaid Services CMS, Red Book, published literature (Prudential
Research Report, 2010; Univita Health, 2010) and internet ven-
dor price lists. For the Canadian survey, the resource costs were
sourced from provincial benefit schemes and drug formularies
(Ontario Ministry of Health and Long-term Care, 1999; Régie
d’Assurance Maladie de Québec (RAMQ), 2008a,b; Ontario Min-
istry of Health and Long-term Care, 2010a; Ontario Ministry of
Health and Long-term Care, 2010b; Ontario Ministry of Health
and Long-term Care, 2010c; Ontario Ministry of Health and Long-
term Care, 2010d), the Canadian Institute for Health Information
(2010a,c), professional associations and internet vendor price lists.
Costs which dated earlier than 2010 were inflated by the appropri-
ate price index. Patient reported expenditures for car and home
adaptations in excess of 1000 US or Canadian dollars were con-
verted to equivalent annual costs with a useful life of nc= 4 years
for car adaptations and nh= 15 for home adaptations and an inter-
est rate of r = 7%. The quantities of measures of care reported by
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the patients were multiplied by these cost rates to determine total
costs by type of service, by component and on the summary level
of total healthcare costs. To estimate the ratios of costs borne by
public and private payers, the costs of each healthcare component
were multiplied by public and private funding ratios specific to
each component, as well as by the public and private funding ratios
observed for the total healthcare costs of the general population.
Public and private funding ratios for the US were sourced from
the Medical Expenditure Panel Survey MEPS (U.S. Department
of Health and Human Services, 2008a,b) and published literature
(Tumlinson et al., 2007), and for Canada, from Canadian Insti-
tute for Health Information (2005) and Health Canada (2001).
The studies were approved by Western Institutional Review Board
(WIRB).
ANALYSES
HEALTHCARE COSTS
Descriptive statistics were used to characterize the distribution of
costs by healthcare component and on the summary level, both for
the entire patient population and by severity of disease category.
The significance of cost differences between severity of disease
categories was assessed by means of the Mann Whitney test. To
put FRDA related healthcare costs into perspective for the US,
they were compared with the healthcare costs measured for the
comparator population of “US adults with two and more chronic
conditions” (Machlin et al., 2008). Correlation analysis was used
to test the association of severity of disease with total healthcare
costs.
COMPLIANCE WITH TREATMENT RECOMMENDATIONS
Schulz et al. (2009) recommended patients to see a neurologist
and a cardiologist at least for one annual neurological, cardiologi-
cal, and hematological evaluation, and an ongoing physiotherapy
and regular speech therapy to address ataxia and dysarthria, the
most characteristic symptoms of FRDA. Compliance was consid-
ered high if 70% or a higher percentage of respondents reported
at least one visit per year to a neurologist and/or a cardiologist, as
well as the performance of one laboratory panel analysis. Compli-
ance of the reported frequency of therapist visits was assessed to
be high if a majority of the patients reported an at least monthly
frequency of visits.
PAYER ANALYSIS
To determine if public and private funding ratios for the healthcare
costs incurred by persons with FRDA were different from the pub-
lic and private funding ratios observed for the general population,
the Wilcoxon signed rank test was applied.
The statistical analysis was performed with IBM® SPSS®
Statistics version 19.0.
RESULTS
DEMOGRAPHICS, RESPONSE RATE
United States
Of the 789 persons in the US who received a link to the elec-
tronic questionnaire 197 submitted a valid data record, which
implies a response rate of 25%. The mean age of the respondents
was 30 years (28–32 years, 95% CI) with the age range spanning
4–72 years. About 92% of the respondents were younger than
55 years, which reflected the average life expectancy of 40–50 years
reported in the literature for this patient population (Pandolfo,
2009; Schulz et al., 2009). The median age of the survey partici-
pants (26 years) was considerably lower than the median age of the
US resident population (36.8 years). Disease onset was reported by
71% of the respondents to have occurred at an age of 20 years and
earlier, confirming the observations reported by Pandolfo (2009).
The respondents’ locations were spread across 21 of 50 US states,
and 52.2% of the respondents were living in the 10 states which
in 2010 hosted 50.2% of the US population (U.S. Census Bureau,
2010).
Canada
Of the 87 Canadian FRDA patients who explicitly accepted to
receive a questionnaire, 57 (65.5%) returned a valid data record.
However, only 43 (49.4%) returned the questionnaire before the
database was closed and so were considered for the analysis.
The mean age of the respondents was 27 years (23–31 years, 95%
CI), and the age range spanned 6–64 years. All but one respon-
dent were 50 years old or younger. Disease onset for 74.4% of
the respondents happened at an age of 20 years and earlier. The
respondents resided in the seven Canadian provinces and terri-
tories which accounted for about 95% of Canada’s population in
2006. A majority of 27 persons or 63% of all respondents lived in
Québec.
The demographics observed in the US and Canadian sam-
ples suggested that these were fairly representative of the FRDA
populations.
SEVERITY OF DISEASE
The respondents classified their current status of disease severity
on a scale including four levels of ambulatory capability ranging
from “no wheelchair use” to “use of a wheelchair all the time.”
For the further analysis the four groups were collapsed into two
categories of “less affected persons” who used a wheelchair never
or only occasionally, and of “severely affected persons” who used
a wheelchair most or all the time. Eta values of 0.671 for the
US and 0.864 for the Canadian sample identified a strong cor-
relation between these severity of disease categories and disease
duration (years since diagnosis). The logistic regression analysis
conducted on the US sample confirmed this observation. The test
included disease duration, age, regular use of idebenone (Catena®
and idebenone products from uncontrolled sources), as well as
the interactions between these potential predictor variables and
showed that disease duration correctly predicted the severity of
disease category in about 80% of the cases, whereas the other vari-
ables exhibited no predictive power. This finding was accepted as
a corroboration of the assumption that the increasing degree of
wheelchair use over time reflects the progressive nature of this
disease.
HEALTHCARE COSTS
Eta values of 0.290 in the US and 0.309 in the Canadian sample
indicated a low moderate correlation of severity of disease and
total healthcare costs.
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United States
The frequency distribution of total healthcare costs in the US
showed a distinct positive skew with the mean costs of 12,850
USD (9224 to 16,477 USD; 95% CI) about three times higher than
the median costs. To generate a common basis for the compari-
son with mean healthcare costs established for US adults with two
and more chronic conditions (Machlin et al., 2008), data records
of FRDA persons of 18 years and younger had to be excluded
from the total sample, and the costs of devices, car and home
adaptations and of stays in long-term care facilities had to be dis-
regarded. Figure 1 illustrates that FRDA related costs (8458 to
18,307 USD; 95% CI) were distinctly higher than the costs mea-
sured for the comparator population (4266 to 4876 USD; 95%
CI). The difference was still clear when the 2005 mean costs of the
comparator population (4571 USD) were inflated to 2010 (6217
USD) by applying the Medical Care component of the US Con-
sumer Price Index (inflated costs not shown in Figure 1). Paid
homecare accounted for the major portion of costs of patients
with annual healthcare costs of more than 100,000 USD. All high-
est cost cases belonged to the category of severely affected persons.
Figure 2 presents the mean costs by healthcare component for
each of the severity of disease categories. The graph confirms the
dominant role the costs of paid homecare and of stays in long-
term care facilities play for severely affected persons, whereas the
less affected persons incurred highest mean costs for therapist
visits, physician visits, and medication. To test the significance
of cost differences between severity of disease categories, Mann
Whitney tests were applied. Costs were significantly higher for the
severely affected than for the less affected persons for homecare
(p< 0.01), prescription medicines (p< 0.05), and car adapta-
tions (p< 0.01). The costs of therapist visits were significantly
higher for the less affected persons (p< 0.05). The cost differ-
ences for all other components were not found to be statistically
significant.
U
S
D
20.000
15.000
10.000
5.000
0
Costs of US Adults with FRDA, 95% CI
Costs of US Adults with Two and More Chronic Conditions, 95% CI
Healthcare costs of US Adults with FRDA versus US Adults 
with Two and More Chronic Conditions
FIGURE 1 | Comparison of mean healthcare costs of US adults with
FRDA and of US adults with two and more chronic conditions (95%
CI). (N.B.: the analysis of healthcare costs of US adults with two and more
chronic conditions by Machlin et al. (2008) was based on MEPS data which
included more than 30,000 individuals. The considerably different sample
size of the compared populations contributed to the different sizes of the
95% confidence intervals).
The dispersion of total healthcare costs was almost four
times larger for the severely affected persons (cost range of 0–
181,131 USD) than for the less affected persons (cost range of
100–47,541 USD).
Canada
The frequency distribution of total healthcare costs measured in
persons with FRDA living in Canada was symmetric, as opposed
to the positively skewed frequency distribution observed in the
US. The mean costs of 34 683 CAD (26 698–42 668 CAD; 95%
CI) were about three times higher than the mean costs mea-
sured in the US survey. This was mainly due to Catena® with
annual costs of about 38 000 CAD. (At the time of this sur-
vey, Catena® was not approved in the United States). The costs
of medication, and particularly of Catena® which was regularly
taken by members of both severity of disease categories, was the
main reason for the shift of the median cost (38 826 CAD) to a
value close to and even higher than the mean costs. Medication
costs were the main driver of the highest costs reported for less
affected persons, and contributed to the highest costs observed
in severely affected persons, together with the costs for homecare
and long-term care facilities. Figure 3 presents the mean costs by
healthcare component for each of the severity of disease categories.
It confirms the dominant role of medication costs in both sever-
ity of disease categories. When medication costs were disregarded,
the pattern of costs by component was similar to the one observed
in the US: costs of the severely affected persons were driven by
paid homecare and institutional care, whereas the costs of the less
affected persons were driven by devices, therapist and physician
services. The results of the Mann Whitney tests revealed that the
significant difference of the distributions of total healthcare cost
across the two severity of disease categories (p< 0.05) was entirely
due to homecare costs which were found to be significantly higher
in severely affected persons than in less affected persons (p< 0.01).
As was observed in the US survey, the dispersion of total healthcare
costs was larger for the severely affected persons (cost range of 329
to 99 752 CAD) than for the less affected persons (cost range of
258 to 49 270 CAD) albeit by a factor of about two compared to a
factor of four measured for the US.
COMPLIANCE WITH BASIC TREATMENT RECOMMENDATIONS
In the US, 86 and 77% of the respondents, respectively, saw a neu-
rologist or a cardiologist, and 66% saw both of these specialists at
least once per year. In Canada, the percentages were 75, 86, and
65% (Table 1). Somewhat lower figures of 72% of the respon-
dents in the US and of 62% in the Canadian sample reported
to have had a laboratory panel analysis done. However, in both
countries, the response rate to this question was only about 30%.
Therefore, the results might not be representative of the FRDA
population. In the US, 51% of the respondents saw a physiother-
apist at least one to two times a year, and 26% of the respondents
saw their physiotherapist at least once a month. A clear major-
ity of 83% of the respondents never saw a speech therapist, and
only 3.5% of the respondents made regular monthly or more fre-
quent use of a speech therapy. This was reflected in a five times
lower average number of visits to speech therapists than to phys-
iotherapists (Table 2). A similar pattern was observed in Canada
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FIGURE 2 | US survey: mean costs of persons with FRDA, by healthcare component and severity of disease category.
where 59% of the respondents saw a physiotherapist at least one
to two times a year and 24% saw the physiotherapist at least
monthly. Eighty seven percent of the respondents never saw a
speech therapist and none used this type of therapy on a regular
basis.
PAYER ANALYSIS
Public and private funding ratios for the general populations
were almost inverse in the US (28%/72%) compared to Canada
(70%/30%) (Table 3).
In the US, the public share of FRDA costs was higher than
the public share of the costs of the general population. How-
ever, the difference was not statistically significant. Homecare costs
accounted for the most important portion of the public payer
share. According to MEPS, in 2008, 86.5% of the costs of “all home
services” were funded from public sources (U.S. Department of
Health and Human Services, 2008a,b).
In Canada, the private share was significantly higher for FRDA’s
healthcare costs than for the general population’s healthcare costs
(35 versus 30%, p< 0.01). The driving force here was medication
costs, which accounted for the most important portion of the pri-
vately funded healthcare costs. On average, 55% of prescription
medicines costs were privately funded (Canadian Institute for
Health Information, 2010b).
LIMITATIONS OF THE STUDY
Due to the lack of specific North American treatment guidance a
European expert panel’s guidance was used to set up the survey
questionnaire. The small number of medical experts in such a rare
disease promotes a close research collaboration across continents.
Whereas this allows to assume that the European treatment recom-
mendations are also accepted in the US and Canada the country
specific funding schemes influence the degree of access to the
recommended healthcare services. Any interpretation of resource
utilization across countries must therefore be accompanied by a
notion of caution.
With the Canadian respondents sampled from the registry
of patients participating in the Catena® access program a selec-
tion bias was introduced which resulted from the fact that all of
these patients had got a prescription for Catena® and 53% of the
participants reported regular use of Catena®, a pharmacological
treatment not available to Canadian patients outside this sample
frame or who did not have adequate private insurance nor qualified
for the statutory health insurance. The healthcare cost estimates
for the Canadian sample are therefore likely to be overstated.
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Table 1 | Percentage of survey respondents who saw specialists and
had a lab analysis done at least once during the 12-months
observation period.
United States (%) Canada (%)
Neurologist 86 75
Cardiologist 77 86
Neurologist+ cardiologist 66 65
Panel of lab analyses 72 62
Although measures were taken to support the respondents’
memory of healthcare services used during the 12-months obser-
vation period, the accuracy of recollection from such a long period
of time may not have been as good as if a prospective patient diary
had been used.
DISCUSSION AND CONCLUSION
The results of the surveys substantiated an impressive breadth
and level of care addressing the broad range of clinical symptoms
associated with FRDA. It did not therefore come as a surprise
that US residents with FRDA were observed to incur considerably
Table 2 | Mean number of visits of the survey respondents to different
types of therapists during the 12-months observation period.
United States Canada
Physiotherapist 10 6
Chiropractor 2 3
Speech therapist 2 0
Dietician 1 0
higher mean healthcare costs than the comparator population of
“US adults with two and more chronic conditions.” Nor was the
marked cost impact which the availability of an orphan drug treat-
ment for FRDA had in Canada an unexpected finding. The use of
paid homecare and stays in long-term care facilities was observed
to be a hallmark and a major cost driver of severe stages of the
disease.
In the US the public versus private funding pattern for health-
care measures utilized by FRDA patients followed the pattern
observed for the general population. In Canada where more than
half of the prescription medicines’ costs are privately funded, the
relatively high costs of Catena®, an orphan drug for the treatment
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Table 3 | Public and private funding ratios in the United States and
Canada for the general population and for persons with FRDA.
United States Canada
Public (%) Private (%) Public (%) Private (%)
General population 28 72 70 30
Persons with FRDA 34 66 65 35
of FRDA, made the private funding ratio for FRDA patients sig-
nificantly exceed the private funding ratio observed in the general
population. Limited availability of private funding may have been
the reason that only about half of the patients with a prescription
for this drug were actually taking it regularly.
Novel healthcare measures resulting in a slowed progression
of the disease may help to preserve patients’ independence longer
and bear the potential of reducing the costs to the healthcare sys-
tems. In addition, a more regular management of dysarthria may
contribute to enhancing the patients’ social capabilities. Reasons
for the relatively low utilization of speech therapy should be fur-
ther investigated with the goal to remove obstacles which may
impair the accessibility of speech therapy and to identify fur-
ther clinical measures to address this characteristic symptom
of FRDA.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/Pharmaceutical_Medicine_
and_Outcomes_Research/10.3389/fphar.2013.00066/abstract
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